Capricor Therapeutics (NASDAQ:CAPR) Hit With Buy Rating From Maxim Group, Analysts Expect $7.0000 Stock Price

May 17, 2018 - By Adrian Erickson

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Logo

Investors sentiment increased to 4.33 in 2017 Q4. Its up 2.53, from 1.8 in 2017Q3. It is positive, as 3 investors sold Capricor Therapeutics, Inc. shares while 0 reduced holdings. 7 funds opened positions while 6 raised stakes. 4.44 million shares or 503.95% more from 735,965 shares in 2017Q3 were reported.

Pennsylvania-based Vanguard Grp Incorporated has invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Brown Advisory accumulated 0.01% or 1.14M shares. 6,500 are owned by Bancorporation Of America Corp De. Financial Architects invested in 0% or 2,000 shares. Acadian Asset Mngmt Limited Liability Corp invested in 0% or 47,489 shares. Apriem Advsr has 0.02% invested in Capricor Therapeutics, Inc. (NASDAQ:CAPR) for 50,000 shares. Royal Bankshares Of Canada reported 232 shares or 0% of all its holdings. Northern Trust has 38,660 shares for 0% of their portfolio. Wells Fargo And Com Mn owns 35,300 shares. Deutsche National Bank & Trust Ag accumulated 3,000 shares. Perceptive Advisors Lc reported 4,000 shares. Blackrock owns 5,616 shares. Citadel Ltd Liability reported 10,009 shares. Financial Bank Of Ny Mellon, a New York-based fund reported 27,442 shares. Granite Point Mgmt Limited Partnership holds 33,750 shares or 0.01% of its portfolio.

Why Has Maxim Group Given Capricor Therapeutics (NASDAQ:CAPR) a $7.0000 Price Target

Stock analysts at Maxim Group has begun coverage on Capricor Therapeutics (NASDAQ:CAPR) with a key Buy rating. The PT for CAPR is exactly $7.0000. It indicates a possible upside of 426.32 % from company’s last stock close.

The stock increased 2.31% or $0.03 during the last trading session, reaching $1.33. About 215,459 shares traded. Capricor Therapeutics, Inc. (NASDAQ:CAPR) has declined 60.12% since May 17, 2017 and is downtrending. It has underperformed by 71.67% the S&P500.

Analysts await Capricor Therapeutics, Inc. (NASDAQ:CAPR) to report earnings on August, 9. They expect $-0.11 earnings per share, up 31.25 % or $0.05 from last year’s $-0.16 per share. After $-0.14 actual earnings per share reported by Capricor Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -21.43 % EPS growth.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. The company has market cap of $38.30 million. The Company’s development stage drug candidates for cardiosphere-derived cells include CAP-1002 that is in Phase I/II clinical trial in subjects with DMD; and CAP-2003 that is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. It has a 14.78 P/E ratio.

More notable recent Capricor Therapeutics, Inc. (NASDAQ:CAPR) news were published by: Seekingalpha.com which released: “Capricor Therapeutics’ (CAPR) CEO Linda Marbán on Q1 2018 Results – Earnings Call Transcript” on May 10, 2018, also Globenewswire.com with their article: “Capricor Therapeutics to Present First Quarter 2018 Financial Results and Corporate Update on May 10” published on May 04, 2018, Streetinsider.com published: “UPDATE: Maxim Group Starts Capricor Therapeutics (CAPR) at Buy” on May 16, 2018. More interesting news about Capricor Therapeutics, Inc. (NASDAQ:CAPR) were released by: Nasdaq.com and their article: “Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update” published on May 10, 2018 as well as Nasdaq.com‘s news article titled: “Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal” with publication date: May 03, 2018.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: